Found: 17
Select item for more details and to access through your institution.
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 16, p. 8851, doi. 10.3390/ijms23168851
- By:
- Publication type:
- Article
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 11, p. 6142, doi. 10.3390/ijms22116142
- By:
- Publication type:
- Article
Tyrosine Hydroxylase Knockdown at the Hypothalamic Supramammillary Nucleus Area Induces Obesity and Glucose Intolerance.
- Published in:
- Neuroendocrinology, 2024, v. 114, n. 5, p. 483, doi. 10.1159/000535944
- By:
- Publication type:
- Article
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
- Published in:
- Journal of Diabetes Research, 2015, v. 2015, p. 1, doi. 10.1155/2015/157698
- By:
- Publication type:
- Article
Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2020, v. 3, n. 1, p. N.PAG, doi. 10.1002/edm2.101
- By:
- Publication type:
- Article
Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats.
- Published in:
- Diabetology & Metabolic Syndrome, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13098-021-00630-x
- By:
- Publication type:
- Article
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
- Published in:
- BMC Endocrine Disorders, 2007, v. 7, p. 3, doi. 10.1186/1472-6823-7-3
- By:
- Publication type:
- Article
Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes.
- Published in:
- Diabetes Care, 2010, v. 33, n. 7, p. 1503, doi. 10.2337/dc09-2009
- By:
- Publication type:
- Article
756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-756-P
- By:
- Publication type:
- Article
1823-P: Bromocriptine (BC) Normalizes Elevated Expression of Liver Genes Involved in Fatty Acid Oxidation, Lipogenesis, Inflammation, and Endoplasmic Reticulum (ER) Stress and Glucose Intolerance of High-Fat/Sucrose Diet-Fed Rats.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1823-P
- By:
- Publication type:
- Article
1083-P: Bromocriptine-QR (BQR) Reduces Hypertriglyceridemia (HTG) in Hypertensive Type 2 Diabetes (T2D) Subjects.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1083-P
- By:
- Publication type:
- Article
1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1070-P
- By:
- Publication type:
- Article
1811-P: Short Term Dopamine D1D2 Receptor Agonist Therapy Induces Long-Term Amelioration of Hyperglycemia in ob/ob Mice.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1811-P
- By:
- Publication type:
- Article
1793-P: Dopamine D1 plus D2 Receptor Coactivation Ameliorates Metabolic Syndrome (MS) and Nonalcoholic Fatty Liver Disease (NAFLD) in Mice.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1793-P
- By:
- Publication type:
- Article
1792-P: Circumventing Gut Exposure to Bromocriptine (b) Administration Multiplies Its Antidiabetes Efficacy vs. Its Equimolar Plasma Level Derived from Oral Dosing.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1792-P
- By:
- Publication type:
- Article
1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1166-P
- By:
- Publication type:
- Article